West Cobar Metals Ltd (ASX:WC1) managing director Matt Szwedzicki talked with Proactive's Jonathan Jackson about the company’s latest metallurgical results from the Bulla Park project. Early-stage testing has delivered high-grade copper, silver, and antimony concentrates with strong recoveries. Szwedzicki described the initial float test results as amazing. A key challenge at Bulla Park has been the presence of tetrahedrite, a less common mineral in Australia. However, recent testing has demonstrated successful separation and recovery processes. The company has now achieved 88% extraction of antimony, a commodity that has surged in value due to reduced exports from China. Szwedzicki also discussed West Cobar’s broader strategy, including plans to optimise metallurgical processes, assess a mineral resource estimate, and advance drilling at Bulla Park. Beyond this, the company is progressing its Salazar project in Western Australia, which holds rare earths, scandium, and alumina resources. The recent acquisition of the Mystique Gold Project further strengthens West Cobar’s portfolio, adding a promising gold exploration target. Stay tuned for more updates from West Cobar Metals. If you enjoyed this interview, give the video a like, subscribe to Proactive’s YouTube channel, and turn on notifications for the latest mining insights. #WestCobarMetals #Copper #Antimony #Mining #ASX #BullaPark #RareEarths #GoldExploration #Metals #Investing #Resources

Hive Digital Technologies Executive Chairman Frank Holmes joined Steve Darling from Proactive to discuss the company’s unaudited Bitcoin production results for February 2025. HIVE mined 89 BTC during the month, bringing its total Bitcoin holdings to 2,620 BTC, valued at approximately $220 million as of February 28, based on a BTC price of $84,000. Holmes highlighted that HIVE's Bitcoin holdings have grown by 23% year-over-year. However, on a month-over-month basis, BTC reserves declined as the company strategically sold a portion of its holdings to reinvest in capital assets, including acquiring Bitfarms’ 200 MW hydro-powered Bitcoin mining facilities in Paraguay. Despite the asset reallocation, HIVE maintained a strong mining capacity, averaging 5.6 Exahash per Second (EH/s) with fleet efficiency at 20.9 Joules per Terahash. The company achieved a peak BTC-only hashrate of 6.2 EH/s and a peak BTC-equivalent hashrate of 6.4 EH/s, with an average daily production rate of 3.2 BTC—equivalent to 16 BTC per Exahash. Looking ahead, HIVE is targeting significant growth in 2025, with plans to quadruple its hashrate from 6 EH/s to 25 EH/s by September. The company’s 300 MW expansion in Paraguay is a key part of this strategy, with phased energization of miners set for calendar Q2 2025. The first 100 MW will be deployed at Yguazú, followed by another 100 MW at Valenzuela, positioning HIVE for substantial scale-up in the competitive Bitcoin mining landscape. #proactiveinvestors #hivedigitaltechnologieslet #tsxv #hive #nasdaq #hive

Medicus Pharma CEO Dr. Raza Bokhari joined Steve Darling from Proactive to share updates on the ongoing SKNJCT-003 clinical study, which is being conducted at nine sites across the United States and aims to randomize 60 patients. An interim analysis conducted after enrolling more than half of the targeted participants has shown encouraging results. The study reports a clinical clearance rate exceeding 60%, with the investigational therapy demonstrating strong tolerability across both tested dosage levels. Notably, no dose-limiting toxicities (DLTs) or serious adverse events (SAEs) have been observed, and there have been no systemic effects or clinically significant abnormalities in laboratory results, ECGs, vital signs, or physical exams. These promising findings will be submitted to the U.S. Food and Drug Administration (FDA) as part of a Type C meeting request in Q2 2025. In parallel, the company is advancing its clinical initiatives for non-invasive basal cell carcinoma treatment with a newly proposed study. This randomized, double-blind, placebo-controlled, multi-center trial has been submitted for approval to the UAE Department of Health. The study aims to enroll up to 36 patients at prominent medical institutions, including Cleveland Clinic Abu Dhabi, Sheikh Shakbout Medical City, Burjeel Medical City, and the American Hospital of Dubai. Participants will be assigned in a 1:1:1 ratio to receive either a placebo or one of two dosage levels of the experimental treatment. This expansion into the UAE represents a significant step forward in the company’s mission to develop innovative, non-invasive therapies for skin cancer, broadening its global clinical footprint and reinforcing its commitment to advancing patient care. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch

Graphene Manufacturing Group CEO Craig Nicol joined Steve Darling from Proactive to share an update as the company continues to make strides in the development of its Graphene Aluminium-Ion Battery technology, a cutting-edge innovation being pursued in collaboration with the University of Queensland and Rio Tinto under a Joint Development Agreement. Nicol told Proactive, to accelerate battery development, GMG has signed a service contract with the Battery Innovation Center (BIC) in Indiana, USA. This partnership will support the next phase of research and optimization, leveraging BIC’s state-of-the-art 40,000-square-foot facility in Newberry, Indiana. As a globally recognized innovation hub, BIC specializes in advancing battery technologies, offering end-to-end support from research and development to prototype manufacturing and low-volume production—a critical advantage for GMG as it scales up its graphene-based energy storage solutions. Nicol emphasized that collaborating with BIC allows GMG to access advanced battery manufacturing infrastructure without incurring the high capital costs of building its own pilot production facility—an investment that could exceed AU$10 million. Through this agreement, GMG will retain full intellectual property (IP) rights over the battery development work, ensuring control over its proprietary technology while optimizing BIC’s cell design expertise and battery manufacturing capabilities. By integrating BIC’s expertise into its scale-up strategy, GMG can streamline the production of sample battery cells before committing to mass production, reducing risks and deferring large capital expenditures until the technology reaches a higher level of readiness. Looking ahead, GMG aims to optimize battery performance, produce initial test cells this year, and engage customers for validation. Nicol noted strong interest from major companies eager to integrate this technology. #proactiveinvestors #graphenemanufacturinggroupltd #BatteryTech #